



ROVI: Press Release

ROVI takes first place in the Sustainalytics world ESG risk ranking for the second year running

- Laboratorios Farmacéuticos ROVI, S.A., (“ROVI”) has improved its ESG risk rating by almost one point, improving its “Low Risk” rating to 16.4 versus 17.3 in 2022 and remaining in first place among the 431 companies rated in the pharmaceutical industry category.
- This result reinforces ROVI as a pharmaceutical sector leader in sustainable business management.

Madrid, 4 August, 2023

For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world rating of environmental, social and corporate governance (ESG) risks drawn up by Sustainalytics, a leading independent ESG research, rating and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. ROVI has revalidated its first place among 431 companies rated in the pharmaceutical industry group and remains in 22nd place among a total of 895 companies rated in the entire sector, which includes “biotechnology companies, pharmaceutical laboratories and laboratory equipment companies.”

In the rating process, Sustainalytics has analysed the company's performance in sustainability aspects considered material in the pharmaceutical sector, highlighting ROVI's sound management of ESG risks related to product quality and safety, corporate governance, business ethics, human capital, the fight against climate change and anti-corruption and anti-bribery practices. ROVI has obtained a higher-than-average score in areas such as the board's involvement in the company's environmental and social aspects, implementation of the environmental policy and

a sound quality and safety programme for products and services, as well as the integration of ethical practices into all tiers of the organisation.

You may consult ROVI's rating on this link:

https://www.rovi.es/sites/default/files/laboratorios_farmaceuticos_rovi_sa_riskratings_summaryreport_08_03_2023.pdf

Commitment to sustainability

In 2022, ROVI approved its *ESG Master Plan 2023-2025*, a document that sets out 19 strategic ESG goals. With a three-year horizon, the Group has established a roadmap for attaining the Sustainable Development Goals (SDGs) of the United Nations Agenda 2030, with which ROVI, as a member of the Global Compact, is aligned.

The Group focuses its action on five priority areas:

- Becoming a leader in governance committed to sustainability.
- Commitment to sustainable management to combat the global environmental challenges: fight against climate change, promotion of the circular economy and efficient water management.
- Positioning itself as a key player in caring for persons and integrating specialised and diverse talent.
- Promoting responsible management of the supply chain, ensuring ethical and environmental standards in each one of its links.
- Promoting R&D&I activities by establishing partnerships with key players.

About ROVI

ROVI is a pan-European pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland, and holds a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, which is already marketed in more than 60 countries around the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe and it is now being marketed in 40 countries. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged

drug release with proven advantages. For further information, please visit www.rovi.es